Lonza Group AG (LZAGY)
USD 65.07
(-1.2%)
USD 65.07
(-1.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.57 Billion CHF | 13.15% |
| 2022 | 6.69 Billion CHF | 0.83% |
| 2021 | 6.63 Billion CHF | -12.05% |
| 2020 | 7.54 Billion CHF | 3.7% |
| 2019 | 7.27 Billion CHF | -4.65% |
| 2018 | 7.63 Billion CHF | 1.25% |
| 2017 | 7.53 Billion CHF | 68.5% |
| 2016 | 4.47 Billion CHF | 8.75% |
| 2015 | 4.11 Billion CHF | -4.59% |
| 2014 | 4.31 Billion CHF | -2.36% |
| 2013 | 4.41 Billion CHF | -5.94% |
| 2012 | 4.69 Billion CHF | 0.64% |
| 2011 | 4.66 Billion CHF | 95.06% |
| 2010 | 2.39 Billion CHF | -6.42% |
| 2009 | 2.55 Billion CHF | -18.71% |
| 2008 | 3.14 Billion CHF | 0.0% |
| 2007 | 3.14 Billion CHF | 36.36% |
| 2006 | 2.3 Billion CHF | -18.87% |
| 2005 | 2.84 Billion CHF | 38.18% |
| 2004 | 2.05 Billion CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.47 Billion CHF | 11.87% |
| 2023 Q2 | 7.3 Billion CHF | 9.13% |
| 2023 FY | 7.57 Billion CHF | 13.15% |
| 2023 Q4 | 7.57 Billion CHF | 3.68% |
| 2022 Q2 | 6.65 Billion CHF | 0.32% |
| 2022 FY | 6.69 Billion CHF | 0.83% |
| 2022 Q4 | 6.69 Billion CHF | 0.51% |
| 2021 Q2 | 7.82 Billion CHF | 3.66% |
| 2021 Q4 | 6.63 Billion CHF | -15.15% |
| 2021 FY | 6.63 Billion CHF | -12.05% |
| 2020 Q4 | 7.54 Billion CHF | 1.88% |
| 2020 Q2 | 7.4 Billion CHF | 1.79% |
| 2020 FY | 7.54 Billion CHF | 3.7% |
| 2019 Q4 | 7.27 Billion CHF | 0.41% |
| 2019 FY | 7.27 Billion CHF | -4.65% |
| 2019 Q2 | 7.24 Billion CHF | -5.05% |
| 2018 Q4 | 7.63 Billion CHF | 0.43% |
| 2018 FY | 7.63 Billion CHF | 1.25% |
| 2018 Q2 | 7.59 Billion CHF | 0.81% |
| 2017 Q4 | 7.53 Billion CHF | 76.1% |
| 2017 FY | 7.53 Billion CHF | 68.5% |
| 2017 Q2 | 4.28 Billion CHF | -4.31% |
| 2016 Q4 | 4.47 Billion CHF | 5.5% |
| 2016 FY | 4.47 Billion CHF | 8.75% |
| 2016 Q2 | 4.24 Billion CHF | 3.09% |
| 2015 Q2 | 4.08 Billion CHF | -5.27% |
| 2015 FY | 4.11 Billion CHF | -4.59% |
| 2015 Q4 | 4.11 Billion CHF | 0.71% |
| 2014 FY | 4.31 Billion CHF | -2.36% |
| 2014 Q4 | 4.31 Billion CHF | -4.69% |
| 2014 Q2 | 4.52 Billion CHF | 2.45% |
| 2013 FY | 4.41 Billion CHF | -5.94% |
| 2013 Q4 | 4.41 Billion CHF | -9.08% |
| 2013 Q2 | 4.85 Billion CHF | 3.45% |
| 2012 Q4 | 4.69 Billion CHF | 0.71% |
| 2012 Q2 | 4.66 Billion CHF | -0.06% |
| 2012 FY | 4.69 Billion CHF | 0.64% |
| 2011 Q2 | 2.26 Billion CHF | -5.31% |
| 2011 Q4 | 4.66 Billion CHF | 106.01% |
| 2011 FY | 4.66 Billion CHF | 95.06% |
| 2010 Q4 | 2.39 Billion CHF | -5.72% |
| 2010 FY | 2.39 Billion CHF | -6.42% |
| 2010 Q2 | 2.53 Billion CHF | -0.74% |
| 2009 FY | 2.55 Billion CHF | -18.71% |
| 2009 Q4 | 2.55 Billion CHF | -15.37% |
| 2009 Q2 | 3.01 Billion CHF | -3.95% |
| 2008 FY | 3.14 Billion CHF | 0.0% |
| 2008 Q4 | 3.14 Billion CHF | 0.0% |
| 2007 FY | 3.14 Billion CHF | 36.36% |
| 2006 FY | 2.3 Billion CHF | -18.87% |
| 2005 FY | 2.84 Billion CHF | 38.18% |
| 2004 FY | 2.05 Billion CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -209739.246% |
| Arrayit Corporation | 7.49 Million USD | -100892.544% |
| Atlantic International Corp. | 3.82 Million USD | -197647.595% |
| Biocept, Inc. | 22.01 Million USD | -34293.313% |
| Bioqual, Inc. | 18.93 Million USD | -39877.846% |
| CardioGenics Holdings Inc | 1.79 Million USD | -421700.824% |
| DermTech, Inc. | 64.75 Million USD | -11591.761% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | -930.105% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | -61025.672% |
| iMD Companies, Inc. | 1.67 Million USD | -452111.662% |
| IDenta Corp. | 1.01 Million USD | -747167.455% |
| Interpace Biosciences, Inc. | 28.15 Million USD | -26788.518% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -2540955.96% |
| InVitro International | 78.99 Thousand USD | -9584657.564% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | -38274.983% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -5855410.955% |
| Medical Imaging Corp. | 9.51 Million USD | -79451.661% |
| NovelStem International Corp. | 4.2 Million USD | -179901.374% |
| Optigenex Inc. | 9.57 Million USD | -79006.691% |
| PharmChem, Inc. | 558.64 Thousand USD | -1355138.639% |
| Proteome Sciences plc | 18.48 Million USD | -40848.557% |
| Response Genetics, Inc | 15.86 Million USD | -47615.384% |
| Rennova Health, Inc. | 49.66 Million USD | -15143.414% |
| RushNet, Inc. | 6.23 Million USD | -121249.731% |
| ScreenPro Security Inc. | 1.6 Million USD | -472913.963% |
| Stella Diagnostics Inc. | 18 Million USD | -41948.485% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -92184.375% |
| Todos Medical Ltd. | 50.15 Million USD | -14994.603% |